Is tuberculosis elimination a reality?

The Lancet Infectious Diseases

Volumn 14, Issue 5, 2014, Pages 364-

  Sotgiu, Giovanni ^a   Migliori, Giovanni Battista ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CONTACT EXAMINATION; ETHNIC AND RACIAL GROUPS; EUROPEAN UNION; HEALTH CARE SYSTEM; HOUSEHOLD; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; NOTE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; TANDEM REPEAT; TUBERCULOSIS CONTROL; UNITED KINGDOM;

EID: 84899416259     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70030-1     Document Type: Note

References (14)

1. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013, 42:156-168. for the Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB.
2. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013, 42:169-179. for the Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB.
3. Global tuberculosis report 2013 2013, WHO, World Health Organization, Geneva.
4. Diel R, Vandeputte J, de Vries G, Stillo J, Wanlin M, Nienhaus A Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J 2014, 43:554-565.
5. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012, 366:2151-2160.
6. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013, 41:1393-1400.
7. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009, 360:2397-2405.
8. Diel R, Loddenkemper R, Zellweger JP, et al. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J 2013, 42:785-801. for the European Forum for TB Innovation.
9. D'Ambrosio L, Dara M, Tadolini M, et al. Tuberculosis elimination: theory and practice in Europe. Eur Respir J 2014, on behalf of the European national programme representatives, published online Jan 16. 10.1183/09031936.00198813.
10. Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middle-income countries 2012, WHO, World Health Organisation, Geneva.
11. Anderson LF, Tamne S, Brown T, et al. Transmission of multidrug-resistant tuberculosis in the UK: a cross-sectional molecular and epidemiological study of clustering and contact tracing. Lancet Infect Dis 2014, published online March 4. http://dx.doi.org/10.1016/S1473-3099(14)70022-2.
12. Progressing towards TB elimination 2010, European Centre for Disease Prevention and Control, ECDC, Stockholm.
13. A framework action plan to fight tuberculosis in the European Union 2008, European Centre for Disease Prevention and Control, EDCD, Stockholm.
14. Broekmans JF, Migliori GB, Rieder HL, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J 2002, 19:765-775. World Health Organization, International Union Against Tuberculosis and Lung DiseaseInternational Union Against Tuberculosis and Lung Disease, Royal Netherlands Tuberculosis Association Working GroupRoyal Netherlands Tuberculosis Association Working Group.